CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) Stock Has Average Target Price of $117.00 According to Brokerages

Shares of CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) have been given an average rating of “Hold” by the five brokerages that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $117.00.

CHEOY has been the subject of a number of recent research reports. Royal Bank Of Canada lowered shares of CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 price objective for the company. in a report on Thursday, July 16th. Jefferies Financial Group lowered shares of CochLear from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. Canaccord Genuity Group cut shares of CochLear from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. Finally, Zacks Research raised shares of CochLear from a “strong sell” rating to a “hold” rating in a research note on Monday, June 22nd.

CochLear Stock Down 0.5%

Shares of CHEOY opened at $45.06 on Monday. CochLear has a 1 year low of $31.82 and a 1 year high of $98.49. The stock has a 50 day simple moving average of $47.49 and a two-hundred day simple moving average of $44.87.

CochLear Company Profile

Cochlear Limited is an Australian medical technology company that develops, manufactures and supplies implantable hearing solutions for people with moderate to profound hearing loss. Its products are designed to help restore access to sound for individuals who may not benefit sufficiently from conventional hearing aids.

The company’s product portfolio includes cochlear implants, sound processors, bone-conduction hearing implants and related accessories and services. Cochlear also provides professional support, rehabilitation resources and connectivity solutions for recipients, hearing-health specialists and caregivers.

Founded in 1981 and headquartered in Sydney, Australia, Cochlear traces its origins to research led by Professor Graeme Clark, whose work contributed to the development of the world’s first multichannel cochlear implant.